Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $27.05 for the day, up 1.35% from the previous closing price of $26.69. In other words, the price has increased by $1.35 from its previous closing price. On the day, 0.71 million shares were traded. NAMS stock price reached its highest trading level at $27.34 during the session, while it also had its lowest trading level at $25.91.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27. On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $42.Citigroup initiated its Buy rating on June 17, 2025, with a $42 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 15 ’25 when Topper James N bought 660 shares for $23.70 per share. The transaction valued at 15,639 led to the insider holds 3,028,524 shares of the business.
Kooij Louise Frederika sold 150,000 shares of NAMS for $3,874,017 on Sep 09 ’25. The Chief Accounting Officer now owns 15,000 shares after completing the transaction at $25.83 per share. On Sep 08 ’25, another insider, Topper James N, who serves as the Director of the company, bought 1,260 shares for $24.99 each. As a result, the insider paid 31,487 and bolstered with 3,027,864 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 3046599680 and an Enterprise Value of 2307765760. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.60 while its Price-to-Book (P/B) ratio in mrq is 3.91. Its current Enterprise Value per Revenue stands at 36.055 whereas that against EBITDA is -13.369.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.01, which has changed by 0.7395499 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.35, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 11.94%, while the 200-Day Moving Average is calculated to be 25.45%.
Shares Statistics:
NAMS traded an average of 903.65K shares per day over the past three months and 1065450 shares per day over the past ten days. A total of 112.51M shares are outstanding, with a floating share count of 73.28M. Insiders hold about 34.94% of the company’s shares, while institutions hold 61.59% stake in the company. Shares short for NAMS as of 1756425600 were 7497579 with a Short Ratio of 8.30, compared to 1753920000 on 7179587. Therefore, it implies a Short% of Shares Outstanding of 7497579 and a Short% of Float of 7.9399999999999995.
Earnings Estimates
The company has 12.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.2. EPS for the following year is -$1.72, with 10.0 analysts recommending between -$1.12 and -$2.52.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.21M, while the lowest revenue estimate was $18.99M, resulting in an average revenue estimate of $27.2M. In the same quarter a year ago, actual revenue was $43.39M
